Oliver Luxxe Assets LLC Invests $4.46 Million in Gilead Sciences, Inc. (NASDAQ:GILD)

Oliver Luxxe Assets LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, HoldingsChannel reports. The firm acquired 48,318 shares of the biopharmaceutical company’s stock, valued at approximately $4,463,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC increased its stake in shares of Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after purchasing an additional 14,680,161 shares in the last quarter. Wellington Management Group LLP grew its stake in Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after buying an additional 11,665,593 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in Gilead Sciences by 350.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock valued at $193,274,000 after acquiring an additional 1,793,145 shares during the period. International Assets Investment Management LLC lifted its position in shares of Gilead Sciences by 8,238.4% during the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock worth $137,708,000 after acquiring an additional 1,622,806 shares in the last quarter. Finally, Pacer Advisors Inc. boosted its holdings in shares of Gilead Sciences by 24.7% in the second quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company’s stock worth $541,310,000 after acquiring an additional 1,564,792 shares during the period. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 453,734 shares of company stock worth $41,902,086. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Trading Down 0.4 %

Shares of GILD traded down $0.35 during trading hours on Monday, hitting $91.06. The company had a trading volume of 4,103,792 shares, compared to its average volume of 3,856,787. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The stock’s 50 day moving average price is $91.81 and its 200 day moving average price is $82.68. The firm has a market cap of $113.48 billion, a P/E ratio of 1,011.78, a P/E/G ratio of 2.24 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the previous year, the company posted $2.29 earnings per share. The business’s revenue was up 7.0% on a year-over-year basis. On average, research analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Analysts Set New Price Targets

A number of analysts recently issued reports on GILD shares. Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. UBS Group upped their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target for the company. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $84.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Twelve research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $96.43.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.